{"id":40179,"date":"1999-07-01T12:05:00","date_gmt":"1999-07-01T10:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie"},"modified":"1999-07-01T12:05:00","modified_gmt":"1999-07-01T10:05:00","slug":"dauer-der-antikoagulation-nach-idiopathischer-thromboembolie","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/","title":{"rendered":"Dauer der Antikoagulation nach idiopathischer Thromboembolie"},"content":{"rendered":"<p>Das Research Committee der British Thoracic Society stellte fest, da\u00df nach einer vierw\u00f6chigen Antikoagulation wegen tiefer Beinvenenthrombose, Lungenembolie (oder beiden) mehr Rezidive beobachtet werden als nach einer Antikoagulation f\u00fcr drei Monate (1, 2). Die schwedische Duration of Anticoagulation-Studie (DURAC 1) zeigte, da\u00df nach Antikoagulation f\u00fcr sechs Monate sich weniger Rezidive ereignen als nach Antikoagulation f\u00fcr [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Das Research Committee der British Thoracic Society stellte fest, da\u00df nach einer vierw\u00f6chigen Antikoagulation wegen tiefer Beinvenenthrombose, Lungenembolie (oder beiden) mehr Rezidive beobachtet werden als nach einer Antikoagulation f\u00fcr drei Monate (1, 2). Die schwedische Duration of Anticoagulation-Studie (DURAC 1) zeigte, da\u00df nach Antikoagulation f\u00fcr sechs Monate sich weniger Rezidive ereignen als nach Antikoagulation f\u00fcr [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[66,609,4763,323,203,612,897,205],"class_list":["post-40179","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antikoagulanzien","tag-beinvenenthrombose","tag-durac-studien","tag-phenprocoumon","tag-thromboembolie","tag-thrombose","tag-venenthrombose","tag-warfarin"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dauer der Antikoagulation nach idiopathischer Thromboembolie - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dauer der Antikoagulation nach idiopathischer Thromboembolie - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Das Research Committee der British Thoracic Society stellte fest, da\u00df nach einer vierw\u00f6chigen Antikoagulation wegen tiefer Beinvenenthrombose, Lungenembolie (oder beiden) mehr Rezidive beobachtet werden als nach einer Antikoagulation f\u00fcr drei Monate (1, 2). Die schwedische Duration of Anticoagulation-Studie (DURAC 1) zeigte, da\u00df nach Antikoagulation f\u00fcr sechs Monate sich weniger Rezidive ereignen als nach Antikoagulation f\u00fcr [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"1999-07-01T10:05:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Dauer der Antikoagulation nach idiopathischer Thromboembolie\",\"datePublished\":\"1999-07-01T10:05:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\\\/\"},\"wordCount\":335,\"keywords\":[\"Antikoagulanzien\",\"Beinvenenthrombose\",\"DURAC-Studien\",\"Phenprocoumon\",\"Thromboembolie\",\"Thrombose\",\"Venenthrombose\",\"Warfarin\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\\\/\",\"name\":\"Dauer der Antikoagulation nach idiopathischer Thromboembolie - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"datePublished\":\"1999-07-01T10:05:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dauer der Antikoagulation nach idiopathischer Thromboembolie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dauer der Antikoagulation nach idiopathischer Thromboembolie - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/","og_locale":"de_DE","og_type":"article","og_title":"Dauer der Antikoagulation nach idiopathischer Thromboembolie - Der Arzneimittelbrief","og_description":"Das Research Committee der British Thoracic Society stellte fest, da\u00df nach einer vierw\u00f6chigen Antikoagulation wegen tiefer Beinvenenthrombose, Lungenembolie (oder beiden) mehr Rezidive beobachtet werden als nach einer Antikoagulation f\u00fcr drei Monate (1, 2). Die schwedische Duration of Anticoagulation-Studie (DURAC 1) zeigte, da\u00df nach Antikoagulation f\u00fcr sechs Monate sich weniger Rezidive ereignen als nach Antikoagulation f\u00fcr [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"1999-07-01T10:05:00+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Dauer der Antikoagulation nach idiopathischer Thromboembolie","datePublished":"1999-07-01T10:05:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/"},"wordCount":335,"keywords":["Antikoagulanzien","Beinvenenthrombose","DURAC-Studien","Phenprocoumon","Thromboembolie","Thrombose","Venenthrombose","Warfarin"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/","name":"Dauer der Antikoagulation nach idiopathischer Thromboembolie - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"datePublished":"1999-07-01T10:05:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/dauer-der-antikoagulation-nach-idiopathischer-thromboembolie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Dauer der Antikoagulation nach idiopathischer Thromboembolie"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=40179"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40179\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=40179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=40179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=40179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}